<div class="container">

<table style="width: 100%;"><tr>
<td>power.dp</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Power of dose-proportionality studies evaluated via Power model
</h2>

<h3>Description</h3>

<p>Calculates the power of dose-proportionality studies using the power model for 
crossover (Latin square) or parallel group designs via a confidence interval
equivalence criterion.
</p>


<h3>Usage</h3>

<pre><code class="language-R">power.dp(alpha = 0.05, CV, doses, n, beta0, theta1 = 0.8, theta2 = 1/theta1, 
         design = c("crossover", "parallel", "IBD"), dm = NULL, CVb)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>alpha</code></td>
<td>

<p>Type 1 error. Commonly set to 0.05.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CV</code></td>
<td>

<p>Coefficient of variation for intra-subject variability if <code>design="crossover"</code> 
or CV of total variability in case of <code>design="parallel"</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>doses</code></td>
<td>

<p>Vector of dose levels. At least two doses have to be given.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>n</code></td>
<td>

<p>Number of subjects. Is total number if given as scalar, else number of subjects
in the (sequence) groups. In the latter case the length of n vector has to be 
the same as length of vector doses.<br>
n has to be &gt;2.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>beta0</code></td>
<td>

<p>‘True’ slope of power model. If missing defaults to <code>1+log(0.95)/log(rd)</code>
where <code>rd</code> is the ratio of highest to lowest dose.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta1</code></td>
<td>

<p>Lower acceptance limit for the ratio of dose normalized means (Rdmn).<br>
Transformes into slope acceptance range as described under item <code>beta0</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta2</code></td>
<td>

<p>Upper acceptance limit for the ratio of dose normalized means (Rdmn).
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>design</code></td>
<td>

<p>Crossover design (default), parallel group design or incomplete block design (IBD).<br>
Crossover design means Latin square design with number of doses as dimension.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>dm</code></td>
<td>

<p>'Design matrix' of the incomplete block design (IBD) if <code>design="IBD"</code>.<br>
This matrix contains the sequences in rows and periods in columns. 
The entry (<em>i</em>, <em>j</em>) of the design matrix corresponds to the dose (index) a subject 
with <em>i</em>-th sequence gets in the <em>j</em>-th period.
Can be obtained f.i. via functions of package <code>crossdes</code> or via function 
<code>bib.CL()</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CVb</code></td>
<td>

<p>Coefficient of variation of the between-subject variability.<br>
Only necessary if <code>design="IBD"</code>. Will be set to 2*CV if missing.
This is only a crude rule of thumb. Better obtain an estimate of CVb from a 
previous crossover study.<br><br>
Set <code>CVb=0</code> if an all-effects-fixed model shall be used. This model gives
higher power than the random subject effects model.
</p>
</td>
</tr>
</table>
<h3>Details</h3>

<p>The power calculations are based on TOST for testing equivalence of the slope 
of the power model with alternativ hypothesis slope = 1.<br>
Power is calculated via non-central t-approximation only.<br>
The calculations are based on mixed effects model (random intercept aka
random subject effect). For <code>design="cossover"</code> or <code>design="parallel"</code>
the results coincide with all-effects-fixed model.
</p>


<h3>Value</h3>

<p>Value of power according to the input arguments.
</p>


<h3>Warning </h3>

<p>This function is ‘experimental’ only since it is not thorougly tested yet. 
Especially for <code>design="IBD"</code> reliable test cases are missing.
</p>


<h3>Author(s)</h3>

<p>D. Labes
</p>


<h3>References</h3>

<p>Patterson S, Jones B. <em>Bioequivalence and Statistics in Clinical Pharmacology.</em> Boca Raton: Chapman &amp; Hall/CRC: 2006. p. 239.<br>
(contains presumably a bug)
</p>
<p>Sethuraman VS, Leonov S, Squassante L, Mitchell TR, Hale MD. <em>Sample size calculation for the Power Model for dose proportionality studies.</em> Pharm Stat. 2007;6(1):35–41. <a href="https://doi.org/10.1002/pst.241">doi:10.1002/pst.241</a>
</p>
<p>Hummel J, McKendrick S, Brindley C, French R. <em>Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion.</em> Pharm. Stat. 2009;8(1):38–49. <a href="https://doi.org/10.1002/pst.326">doi:10.1002/pst.326</a>
</p>


<h3>See Also</h3>

<p><code>sampleN.dp</code>, <code>bib.CL</code>
</p>


<h3>Examples</h3>

<pre><code class="language-R"># using all the defaults, i.e. latin square crossover design, alpha=0.05, 
# beta0=1+log(0.95)/log(rd), theta1=0.8, theta2=1.25
power.dp(CV = 0.2, doses = c(1,2,8), n = 15)
#
# period balanced IBD with 3 doses, 2 periods and 3 sequences,
ibd &lt;- matrix(c(1, 2, 3, 2, 3, 1), nrow = 3, ncol = 2)
power.dp(CV = 0.2, doses = c(1,2,8), n = 12, design = "IBD", dm = ibd)
# considerably lower than 3x3 Latin square
</code></pre>


</div>